1. Home
  2. BDRX vs JAGX Comparison

BDRX vs JAGX Comparison

Compare BDRX & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$3.01

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.38

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDRX
JAGX
Founded
2000
2013
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.2M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
BDRX
JAGX
Price
$3.01
$2.38
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
17.3K
60.9K
Earning Date
09-12-2025
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
N/A
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.22
52 Week High
$11.88
$8.00

Technical Indicators

Market Signals
Indicator
BDRX
JAGX
Relative Strength Index (RSI) 44.96 43.16
Support Level $2.97 $1.78
Resistance Level $4.39 $2.43
Average True Range (ATR) 0.24 0.28
MACD -0.02 -0.14
Stochastic Oscillator 8.75 8.96

Price Performance

Historical Comparison
BDRX
JAGX

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: